Valneva SE (INRLF)
OTC GREY OTC GREY Primary 
Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study
Valneva said that antibody levels remained well above baseline across all six Lyme disease serotypes and all age groups in the trial.
Valneva SE (VALN) Q3 2025 Earnings Call Transcript
Valneva SE ( VALN ) Q3 2025 Earnings Call November 20, 2025 9:00 AM EST Company Participants Joshua Drumm - Vice President of Investor Relations Thomas Lingelbach - President, CEO & Director Peter Buhler - Chief Financial Officer Conference Call Participants Vamil Divan - Guggenheim Securities, LLC, Research Division Maurice Raycroft - Jefferies LLC, Research Division Romy O'Connor - Van Lanschot Kempen NV Presentation Operator Good day, and thank you for standing by. Welcome to the Valneva 9 Months 2025 Financial Results Conference Call and Webcast.
Valneva SE (VALN) Q2 2025 Earnings Call Transcript
Valneva SE (NASDAQ:VALN ) Q2 2025 Earnings Conference Call August 12, 2025 9:00 AM ET Company Participants Joshua Drumm - Vice President of Investor Relations Peter Buhler - Chief Financial Officer Thomas Lingelbach - President, CEO & Director Conference Call Participants Damien Choplain - Stifel, formerly Bryan Garnier & Co., Research Division Mohamad Amin Makarem - Jefferies LLC, Research Division Rajan Sharma - Goldman Sachs Group, Inc., Research Division Sebastiaan van der Schoot - Unidentified Company Joshua Drumm Thank you, operator. Hello, and thank you for joining us to discuss Valneva's first half 2025 results and corporate update.
UK's MHRA suspends Valneva's chikungunya vaccine for elderly
UK's medicine regulator said on Monday it has temporarily restricted the use of French vaccine maker Valneva's shot to treat chikungunya, a virus transmitted by mosquitoes, in people aged 65 and above as a precautionary measure.
Valneva SE (VALN) Q1 2025 Earnings Call Transcript
Valneva SE (NASDAQ:VALN ) Q1 2025 Earnings Conference Call May 7, 2025 9:00 AM ET Company Participants Joshua Drumm - Vice President-Global Investor Relations Thomas Lingelbach - Chief Executive Officer Peter Bühler - Chief Financial Officer Conference Call Participants Maury Raycroft - Jefferies Rajan Sharma - Goldman Sachs Vamil Divan - Guggenheim Securities. Samir Devani - Rx Securities Oscar Haffen Lamm - Bryan, Garnier & Co. Simon Scholes - First Berlin Joshua Drumm Thank you.
Valneva SE: Still Undervalued Travel Vaccine Bet With Robust 2025 Guidance
Valneva SE offers exposure to a robust travel vaccine portfolio that includes Ixiaro, Dukoral, and Ixchiq. Ixiaro generated roughly €94.1 million in 2024 and remains Valneva's main revenue vertical. Dukoral contributed with €32.3 million in sales in 2024 and provides some revenue diversification alongside Ixiaro in the traveler-vaccine niche.
Valneva SE (VALN) Q4 2024 Earnings Call Transcript
Valneva SE (NASDAQ:VALN ) Q4 2024 Earnings Conference Call March 20, 2025 10:00 AM ET Company Participants Joshua Drumm – Vice President-Global Investor Relations Thomas Lingelbach – Chief Executive Officer Peter Bühler – Chief Financial Officer Conference Call Participants Suzanne Van Voorthuizen – Van Lanschot Kempen Samir Devani – Rx Securities Rajan Sharma – Goldman Sachs Oscar Haffen Lamm – Bryan, Garnier Vamil Divan – Guggenheim Securities Maury Raycroft – Jefferies Joshua Drumm Thank you. Hello, and thank you for joining us to discuss Valneva's Full Year 2024 Results and Corporate Update.
Valneva Is A 'Buy' As A First-Mover In Chikungunya
Valneva Is A 'Buy' As A First-Mover In Chikungunya
Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single Shot
On Tuesday, Valneva SE VALN reported Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, Ixchiq.
Valneva SE (VALN) Q3 2024 Earnings Call Transcript
Valneva SE (NASDAQ:VALN ) Q3 2024 Earnings Conference Call November 7, 2024 9:00 AM ET Company Participants Thomas Lingelbach - Chief Executive Officer Peter Buhler - Chief Financial Officer Joshua Drumm - Vice President of Investor Relations Conference Call Participants Maury Raycroft - Jefferies Chiara Montironi - Van Lanschot Kempen Ed White - HC Wainwright Rajan Sharma - Goldman Sachs Samir Devani - Rx Securities Joshua Drumm Thank you for joining us to discuss Valneva's Financial Results for the First Nine Months of 2024 and a Corporate Update. It's my pleasure to welcome you today.
EU regulator recommends use of Valneva's chikungunya vaccine
The European Medicines Agency (EMA) recommended the use of Valneva's single-shot vaccine for chikungunya virus, the regulator said on Friday.
